Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preparation and immunogenic properties of a recombinant West Nile subunit vaccine.
Lieberman MM, Clements DE, Ogata S, Wang G, Corpuz G, Wong T, Martyak T, Gilson L, Coller BA, Leung J, Watts DM, Tesh RB, Siirin M, Travassos da Rosa A, Humphreys T, Weeks-Levy C. Lieberman MM, et al. Among authors: martyak t. Vaccine. 2007 Jan 5;25(3):414-23. doi: 10.1016/j.vaccine.2006.08.018. Epub 2006 Aug 30. Vaccine. 2007. PMID: 16996661 Free PMC article.
Preclinical and clinical development of a dengue recombinant subunit vaccine.
Manoff SB, George SL, Bett AJ, Yelmene ML, Dhanasekaran G, Eggemeyer L, Sausser ML, Dubey SA, Casimiro DR, Clements DE, Martyak T, Pai V, Parks DE, Coller BA. Manoff SB, et al. Among authors: martyak t. Vaccine. 2015 Dec 10;33(50):7126-34. doi: 10.1016/j.vaccine.2015.09.101. Epub 2015 Oct 14. Vaccine. 2015. PMID: 26458804 Review.
Advances in flavivirus vaccine development.
Coller BA, Clements DE, Martyak T, Yelmene M, Thorne M, Parks DE. Coller BA, et al. Among authors: martyak t. IDrugs. 2010 Dec;13(12):880-4. IDrugs. 2010. PMID: 21154147 Review.
A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations.
Van Hoeven N, Joshi SW, Nana GI, Bosco-Lauth A, Fox C, Bowen RA, Clements DE, Martyak T, Parks DE, Baldwin S, Reed SG, Coler RN. Van Hoeven N, et al. Among authors: martyak t. PLoS One. 2016 Feb 22;11(2):e0149610. doi: 10.1371/journal.pone.0149610. eCollection 2016. PLoS One. 2016. PMID: 26901122 Free PMC article.
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.
Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators. Ellis SG, et al. N Engl J Med. 2015 Nov 12;373(20):1905-15. doi: 10.1056/NEJMoa1509038. Epub 2015 Oct 12. N Engl J Med. 2015. PMID: 26457558 Free article. Clinical Trial.
Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.
Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. Kereiakes DJ, et al. JAMA. 2015 Mar 17;313(11):1113-21. doi: 10.1001/jama.2015.1671. JAMA. 2015. PMID: 25781440 Free PMC article. Clinical Trial.
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Mauri L, et al. N Engl J Med. 2014 Dec 4;371(23):2155-66. doi: 10.1056/NEJMoa1409312. Epub 2014 Nov 16. N Engl J Med. 2014. PMID: 25399658 Free PMC article. Clinical Trial.
17 results